Cargando…

Genomic alterations of ERBB receptors in cancer: clinical implications

The ERBB family of receptor tyrosine kinases has been implicated in carcinogenesis for over three decades with rigorous attention to EGFR and HER2. ERBB receptors, consisting of EGFR, HER2, HER3, and HER4 are part of a complicated signaling network that activates downstream signaling pathways includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Rosalin, Hanker, Ariella B., Garrett, Joan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768410/ https://www.ncbi.nlm.nih.gov/pubmed/29371993 http://dx.doi.org/10.18632/oncotarget.22825

Ejemplares similares

HER3 Alterations in Cancer and Potential Clinical Implications
por: Kilroy, Mary Kate, et al.
Publicado: (2022)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

HER3 signaling and targeted therapy in cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
por: Jin, Wook
Publicado: (2020)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
por: Roepstorff, Kirstine, et al.
Publicado: (2008)

Activating HER3 mutations in breast cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

Targeting of erbB3 receptor to overcome resistance in cancer treatment
por: Ma, Jian, et al.
Publicado: (2014)

Peptide G-Protein-Coupled Receptors and ErbB Receptor Tyrosine Kinases in Cancer
por: Moody, Terry W., et al.
Publicado: (2023)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

ERBB receptors in cancer: signaling from the inside
por: Arteaga, Carlos L
Publicado: (2011)

Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
por: Hervent, Anne-Sophie, et al.
Publicado: (2012)

Regulation of ErbB Receptors by the Ca(2+) Sensor Protein Calmodulin in Cancer
por: Villalobo, Antonio
Publicado: (2023)

ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics
por: Alaoui-Jamali, Moulay A., et al.
Publicado: (2015)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
por: Yuan, Long, et al.
Publicado: (2020)

DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability
por: Ma, Zhikun, et al.
Publicado: (2018)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Targeting ERBB2 mutations in solid tumors: biological and clinical implications
por: Cousin, Sophie, et al.
Publicado: (2018)

The ErbB receptor tyrosine kinases and their roles in cancer
por: Hynes, NE
Publicado: (2003)

Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
por: Guo, Yun, et al.
Publicado: (2020)

ERBB signaling in CTCs of ovarian cancer and glioblastoma
por: Geethadevi, Anjali, et al.
Publicado: (2017)

The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
por: Alanazi, Samar M., et al.
Publicado: (2023)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

Uteroplacental insufficiency alters rat hippocampal cellular phenotype in conjunction with ErbB receptor expression
por: Fung, Camille, et al.
Publicado: (2012)

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

Role of ErbB Receptors in Cancer Cell Migration and Invasion
por: Appert-Collin, Aline, et al.
Publicado: (2015)

Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
por: Shih, Andrew J., et al.
Publicado: (2011)

Regulation of ERBB3/HER3 signaling in cancer
por: Mujoo, Kalpana, et al.
Publicado: (2014)

Estrogen receptor transcription and transactivation: ErbB family of receptors in breast cancer
por: Hynes, NE, et al.
Publicado: (2001)

Insights on the Functional Interaction between Group 1 Metabotropic Glutamate Receptors (mGluRI) and ErbB Receptors
por: Ledonne, Ada, et al.
Publicado: (2020)

Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications
por: Silverman, Brittany R., et al.
Publicado: (2016)

Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers
por: Vernimmen, D, et al.
Publicado: (2003)

The interactome of human EGF/ErbB receptors
por: Uetz, Peter, et al.
Publicado: (2006)

ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases
por: Spencer, Kathryn S.R., et al.
Publicado: (2000)

Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma
por: Meyers, Nora, et al.
Publicado: (2020)

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
por: Hutcheson, Iain R, et al.
Publicado: (2011)

Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis
por: Tsai, Yuh-Shyan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7p3qecilt84qitmgqhldpbsgdt